| Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis |
137 |
| Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates |
85 |
| Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review |
45 |
| Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype or 6 Infection Without Cirrhosis |
40 |
| AGA Institute Clinical Practice Update: Endoscopic Submucosal Dissection in the United States |
40 |
| Acetyl-CoA carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis |
39 |
| Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants |
38 |
| Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis |
38 |
| Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians |
37 |
| Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials |
33 |
| Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease |
33 |
| Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis |
32 |
| Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases |
29 |
| The Unregulated Probiotic Market |
29 |
| High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study |
27 |
| Analysis of Fine-Needle Biopsy vs Fine-Needle Aspiration in Diagnosis of Pancreatic and Abdominal Masses: A Prospective, Multicenter, Randomized Controlled Trial |
27 |
| Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis |
26 |
| Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases |
24 |
| The Gut-Brain Axis and the Microbiome: Mechanisms and Clinical Implications |
24 |
| Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis |
24 |
| Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis |
24 |
| Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States |
24 |
| Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes |
23 |
| Prebiotics and Probiotics in Digestive Health |
23 |
| Physician Burnout: The Hidden Health Care Crisis |
22 |
| Normal Values of Esophageal Distensibility and Distension-Induced Contractility Measured by Functional Luminal Imaging Probe Panometry |
22 |
| Compared Abilities of Endoscopic Techniques to Increase Colon Adenoma Detection Rates: A Network Meta-analysis |
22 |
| Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency |
21 |
| Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases |
21 |
| Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease |
20 |
| Increasing Prescription of Opiates and Mortality in Patients With Inflammatory Bowel Diseases in England |
20 |
| Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma |
19 |
| Association of Vedolizumab Level, Anti-Drug Antibodies, and alpha 4 beta 7 Occupancy With Response in Patients With Inflammatory Bowel Diseases |
19 |
| Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis |
19 |
| Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function |
19 |
| The Gut Microbiome in Adult and Pediatric Functional Gastrointestinal Disorders |
19 |
| Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage |
19 |
| Cost-Effectiveness of Colorectal Cancer Screening Strategies-A Systematic Review |
19 |
| AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review |
18 |
| Increased Incidence of Pseudoaneurysm Bleeding With Lumen-Apposing Metal Stents Compared to Double-Pigtail Plastic Stents in Patients With Peripancreatic Fluid Collections |
18 |
| Diagnostic Performance of Measurement of Fecal Elastase-1 in Detection of Exocrine Pancreatic Insufficiency: Systematic Review and Meta-analysis |
18 |
| Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis |
18 |
| Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain Fusobacterium nucleatum |
17 |
| The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage |
17 |
| Health-Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review |
17 |
| Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis |
17 |
| Patient-Reported Outcome Measures for Use in Clinical Trials and Clinical Practice in Inflammatory Bowel Diseases: A Systematic Review |
17 |
| Heterogeneity of Colorectal Cancer Risk Factors by Anatomical Subsite in 10 European Countries: A Multinational Cohort Study |
17 |
| Volatile Organic Compounds in Feces Associate With Response to Dietary Intervention in Patients With Irritable Bowel Syndrome |
17 |
| Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis |
17 |
